Brief: Medigene: Dosing Of First Patient In Phase I/II Trial With TCR Therapy MDG1011 For Various Blood Cancers

Medigene AG

26/02/2019 11:37

Feb 26 (Reuters) - MEDIGENE AG  MDG1k.DE :
    * MEDIGENE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE I/II
TRIAL
WITH TCR THERAPY MDG1011 FOR VARIOUS BLOOD CANCERS

Source text for Eikon:  ID:nPexh4kFDa 
Further company coverage:  MDG1k.DE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))